Table 3 Demographics and clinical characteristics of patients with DNSA in the validation cohort
Predictors | All (n = 74) | Life-threatening complications | |
|---|---|---|---|
Yes (n = 15) | No (n = 59) | ||
Age, median, (IQR), years | 53.0 (42.8–59.8) | 58.0 (46.0–68.0) | 52.0 (41.0.0–57.0) |
Sex, male, n (%) | 59 (79.7) | 14 (93.3) | 45 (76.3) |
Multispace involvement, n (%) | 37 (50.0) | 15 (100.0) | 22 (37.3) |
Gas formation, n (%) | 24 (32.4) | 10 (66.7) | 14 (23.7) |
Dyspnea, n (%) | 13 (17.6) | 7 (46.7) | 6 (10.2) |
Primary regions of infection | Â | Â | Â |
 Suprahyoid region, n (%) | 51 (68.9) | 14 (93.3) | 37 (62.7) |
 Infrahyoid region, n (%) | 18 (24.3) | 0 (0.0) | 18 (30.5) |
 Retropharyngeal region, n (%) | 5 (6.8) | 1 (6.7) | 4 (6.8) |
Laboratory test | Â | Â | Â |
 NEUT, median, (IQR), 109/L | 11.3 (8.7–14.7) | 13.0 (11.6–20.8) | 10.2 (8.4–13.4) |
 PLR, median, (IQR) | 172.5 (115.5–257.1) | 231.6 (160.1–420.4) | 157.4 (113.5–241.4) |
 Albumin, median, (IQR), g/L | 38.0 (33.4–41.9) | 34.6 (27.8–35.1) | 39.4 (33.9–42.5) |